Isis licenses meningococcus vaccine to Novartis
This article was originally published in Scrip
Executive Summary
Isis Innovation, the University of Oxford's technology transfer company, has issued a worldwide exclusive licence to NovartisVaccines and Diagnostics for a vaccine candidate against meningococcus bacteria.